Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development

Xiang, Dongxi; He, Aina; Zhou, Rong; Wang, Yonggang; Xiao, Xiuying; Gong, Ting; Kang, Wenyan; Lin, Xiaolin; Wang, Xiaochen; PDO-based DST Consortium; Liu, Lianxin; Chen, Ye-Guang; Gao, Shaorong; Liu, Yingbin

doi:10.7150/thno.96027

Nanotheranostics

International Journal of Biological Sciences

International Journal of Medical Sciences

Journal of Cancer

open access Global reach, higher impact

Full Text | PDF

Theranostics 2024; 14(8):3300-3316. doi:10.7150/thno.96027 This issue Cite

Review

Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development

Dongxi Xiang^1,2#✉, Aina He^3#, Rong Zhou^4,5#, Yonggang Wang^3#, Xiuying Xiao^6#, Ting Gong^7#, Wenyan Kang^8,9#, Xiaolin Lin^6#, Xiaochen Wang^10#, PDO-based DST Consortium¹¹, Lianxin Liu^12,13✉, Ye-Guang Chen^14,15✉, Shaorong Gao^16,17,18✉, Yingbin Liu^1,2✉

1. State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Shanghai Jiaotong University School of Medicine, Shanghai 200232, PRC
2. Department of Biliary-Pancreatic Surgery, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200127, PRC
3. Department of Oncology, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai 200233 PRC
4. Department of Oral and Maxillofacial-Head and Neck Oncology, Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200125, PRC
5. National Center of Stomatology, National Clinical Research Center for Oral Disease, Shanghai 200011, PRC
6. Department of Oncology, Ren Ji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, PRC
7. Department of Oncology, Tianjin Medical University General Hospital, Tianjin 300052, PRC
8. Department of Neurology and Institute of Neurology, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200025, PRC
9. Department of Neurology, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine (Boao Research Hospital), Hainan 571434, PRC
10. Department of Surgical Oncology, Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88, Jiefang Road, Hangzhou, Zhejiang 310009, PRC
11. PDO-based DST Consortium
12. Department of Hepatobiliary Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Anhui 230001, PRC
13. Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, Anhui Provincial Clinical Research Center for Hepatobiliary Diseases, Hefei, Anhui 230001, PRC
14. The State Key Laboratory of Membrane Biology, Tsinghua-Peking Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing 100190, PRC
15. The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, School of Basic Medicine, Jiangxi Medical College, Nanchang University, Nanchang 330047, China
16. Translational Medical Center for Stem Cell Therapy & Institute for Regenerative Medicine, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai 200120, PRC
17. Frontier Science Center for Stem Cell Research, Tongji University, 1239 Siping Road, Shanghai 200092, PRC
18. Shanghai Key Laboratory of Maternal-Fetal Medicine, Clinical and Translational Research Center of Shanghai First Maternity and Infant Hospital, School of Life Sciences and Technology, Tongji University, Shanghai 200092, PRC
#These authors contribute equally to the work.

Citation:

Xiang D, He A, Zhou R, Wang Y, Xiao X, Gong T, Kang W, Lin X, Wang X, PDO-based DST Consortium, Liu L, Chen YG, Gao S, Liu Y. Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development. Theranostics 2024; 14(8):3300-3316. doi:10.7150/thno.96027. https://www.thno.org/v14p3300.htm

Other styles

Abstract

Patient-derived organoids (PDOs) have emerged as a promising platform for clinical and translational studies. A strong correlation exists between clinical outcomes and the use of PDOs to predict the efficacy of chemotherapy and/or radiotherapy. To standardize interpretation and enhance scientific communication in the field of cancer precision medicine, we revisit the concept of PDO-based drug sensitivity testing (DST). We present an expert consensus-driven approach for medication selection aimed at predicting patient responses. To further standardize PDO-based DST, we propose guidelines for clarification and characterization. Additionally, we identify several major challenges in clinical prediction when utilizing PDOs.

Keywords: Organoid, Patient-derived organoids (PDOs), Precision medicine, Drug sensitivity testing (DST), Expert consensus

Citation styles

APA

Xiang, D., He, A., Zhou, R., Wang, Y., Xiao, X., Gong, T., Kang, W., Lin, X., Wang, X., PDO-based DST Consortium, Liu, L., Chen, Y.G., Gao, S., Liu, Y. (2024). Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development. Theranostics, 14(8), 3300-3316. https://doi.org/10.7150/thno.96027.

ACS

Xiang, D.; He, A.; Zhou, R.; Wang, Y.; Xiao, X.; Gong, T.; Kang, W.; Lin, X.; Wang, X.; PDO-based DST Consortium; Liu, L.; Chen, Y.G.; Gao, S.; Liu, Y. Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development. Theranostics 2024, 14 (8), 3300-3316. DOI: 10.7150/thno.96027.

NLM

CSE

Xiang D, He A, Zhou R, Wang Y, Xiao X, Gong T, Kang W, Lin X, Wang X, PDO-based DST Consortium, Liu L, Chen YG, Gao S, Liu Y. 2024. Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development. Theranostics. 14(8):3300-3316.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.